Increased expression of peripheral benzodiazepine receptors and diazepam binding inhibitor in human tumors sited in the liver

doi:10.1016/S0024-3205(99)00487-7

Life Sciences

Volume 65, Issue 21, 15 October 1999, Pages 2223-2231

https://doi.org/10.1016/S0024-3205(99)00487-7 Get rights and content

Abstract

The peripheral benzodiazepine receptor system triggers intracellular metabolic events and has been associated with cell proliferation. Its endogenous ligand, the diazepam binding inhibitor, contributes to steroidogenesis by promoting cholesterol delivery to the inner mitochondrial membrane. The present study was undertaken to verify whether this system is altered in tumors sited in the liver. Peripheral benzodiazepine receptors and diazepam binding inhibitor were studied using immunocytochemistry and in situ hybridization in 9 human tumors sited in the liver, in liver hyperplasia, cirrhotic nodular regeneration, intestinal adenocarcinoma and in surrounding non-tumoral tissue. Immunocytochemical staining and in situ hybridization demonstrated that peripheral benzodiazepine receptors and diazepam binding inhibitor were more prominently expressed in neoplastic cells than in non-tumoral tissue. They were present in the same cells, suggesting that diazepam binding inhibitor may act in an intracrine manner in these cells. Higher peripheral benzodiazepine receptors and diazepam binding inhibitor expression in tumor cells suggest an implication of this system in the metabolism of neoplastic cells. Furthermore the evaluation of peripheral benzodiazepine receptor and diazepam binding inhibitor expression might be useful in evaluating malignancy and in diagnostic approaches of tumors in liver tissue.

References (35)

R.R.H. Anholt et al.
J. Biol. Chem.
(1986)
M.J. Woods et al.
Biochemical Pharmacology
(1996)
B.O. Oke et al.
Mo. Cell. Endocrinol.
(1992)
E. Costa et al.
Life Sci.
(1991)
K.E. Krueger
Biochem. Biophys. Acta
(1995)
K.E. Krueger et al.
J. Biol. Chem.
(1990)
V. Papadopoulos et al.
J. Biol. Chem.
(1991)
E. Slobodyansky et al.
B. Regul. Pept.
(1994)
M. Pawlikowski et al.
Life Sci.
(1987)
P. Carayon et al.
Blood
(1996)

I. Venturini et al.

Life Sci.

(1998)

I. Venturini et al.

Regul. Pept.

(1998)

R. Van Hillegersberg et al.

Gastroenterology

(1992)

A. Guidotti et al.

Pharmacology

(1979)

J.F. Tallman et al.

Annu. Rev. Neurosci.

(1985)

C. Braestrup et al.

L. Antkiewicz-Michaluk et al.

Mol. Pharmacol.

(1988)

Cited by (59)

The mitochondrial translocator protein (TSPO, 18 kDa): A key multifunctional molecule in liver diseases
2023, Biochimie
Translocator protein (TSPO, 18 kDa), previously known as peripheral-type benzodiazepine receptor, is an evolutionarily conserved and tryptophan-rich 169-amino-acid protein located on the outer mitochondrial membrane. TSPO plays a crucial role in various fundamental physiological functions and cellular processes. Its expression is altered in pathological conditions, thus rendering TSPO a potential tool for diagnostic imaging and an appealing therapeutic target. The investigation of synthetic TSPO ligands as both agonists and antagonists has provided valuable insights into the regulatory mechanisms and functional properties of TSPO. Recently, accumulating evidence has highlighted the significance of TSPO in liver diseases. However, a comprehensive summary of TSPO function in the normal liver and diverse liver diseases is lacking. This review aims to provide an overview of recent advances in understanding TSPO function in both normal liver cells and various liver diseases, with a particular emphasis on its involvement in liver fibrosis and inflammation and addresses the existing knowledge gaps in the field that require further investigation.
Endozepines and their receptors: Structure, functions and pathophysiological significance
2020, Pharmacology and Therapeutics
The existence of specific binding sites for benzodiazepines (BZs) in the brain has prompted the search for endogenous BZ receptor ligands designated by the generic term « endozepines ». This has led to the identification of an 86-amino acid polypeptide capable of displacing [³H]diazepam binding to brain membranes, thus called diazepam-binding inhibitor (DBI). It was subsequently found that the sequence of DBI is identical to that of a lipid carrier protein termed acyl-CoA-binding protein (ACBP). The primary structure of DBI/ACBP has been well preserved, suggesting that endozepines exert vital functions. The DBI/ACBP gene is expressed by astroglial cells in the central nervous system, and by various cell types in peripheral organs. Endoproteolytic cleavage of DBI/ACBP generates several bioactive peptides including a triakontatetraneuropeptide that acts as a selective ligand of peripheral BZ receptors/translocator protein, and an octadecaneuropeptide that activates a G protein-coupled receptor and behaves as an allosteric modulator of the GABA_AR. Although DBI/ACBP is devoid of a signal peptide, endozepines are released by astrocytes in a regulated manner. Consistent with the diversity and wide distribution of BZ-binding sites, endozepines appear to exert a large array of biological functions and pharmacological effects. Thus, intracerebroventricular administration of DBI or derived peptides induces proconflict and anxiety-like behaviors, and reduces food intake. Reciprocally, the expression of DBI/ACBP mRNA is regulated by stress and metabolic signals. In vitro, endozepines stimulate astrocyte proliferation and protect neurons and astrocytes from apoptotic cell death. Endozepines also regulate neurosteroid biosynthesis and neuropeptide expression, and promote neurogenesis. In peripheral organs, endozepines activate steroid hormone production, stimulate acyl chain ceramide synthesis and trigger pro-inflammatory cytokine secretion. The expression of the DBI/ACBP gene is enhanced in addiction/withdrawal animal models, in patients with neurodegenerative disorders and in various types of tumors. We review herein the current knowledge concerning the various actions of endozepines and discuss the physiopathological implications of these regulatory gliopeptides.
Metal complexes targeting the Translocator Protein 18 kDa (TSPO)
2017, Coordination Chemistry Reviews
Citation Excerpt :
Moreover, heterogeneous cell type-specific TSPO expression has been found in several tissues [7,8] and subcellular localization studies have demonstrated that TSPO is localized primarily on the outer mitochondrial membrane [7,9,10] but also in Golgi apparatus, lysosomes and peroxisomes [11], and on plasma membrane [12]. Interestingly, TSPO is overexpressed in a variety of tumors (e.g., certain brain tumors, ovarian cancer, liver tumors, breast carcinoma, colorectal cancer, etc.) and its expression appears to be related to the degree of tumor malignancy [13–16]. In addition, TSPO is overexpressed on activated microglial cells localized in lesioned brain areas of patients with neurodegenerative or neuroinflammatory diseases like Alzheimer’s disease, Huntington’s disease, and multiple sclerosis [17,18].
Since the discovery of antitumor activity of cisplatin in the late 60’s, the development of metal-based drugs has had an enormous burst with the aim of to increase the anti-cancer activity, lower side effects and promote specific accumulation to the target cells or organs. Indeed, a new discipline, called medicinal inorganic chemistry, has born where metal ions play a fundamental role. This review provides a comprehensive overview of various metal complexes targeting the Translocator Protein (TSPO), an 18 kDa high affinity cholesterol- and drug-binding protein found mostly in the outer mitochondrial membrane and formerly known as peripheral-type benzodiazepine receptor. TSPO distribution in healthy tissues varies considerably; in contrast, aberrant expression of TSPO has been noted in several pathological specimens including neurodegenerative diseases and cancers. These findings suggest that TSPO-targeted therapy and imaging may have utility in the treatment and visualization of diseases expressing high density of TSPO. In this review, potential applications in cancer diagnosis and therapy will be discussed.
Long-chain acyl-CoA esters in metabolism and signaling: Role of acyl-CoA binding proteins
2015, Progress in Lipid Research
Citation Excerpt :
A number of external cues have been shown to increase ACBP expression in selected areas of rat brain, including acute stress [187,188], psychological but not physical stress [189], alcohol intake [190–193], nicotine [194–196], diazepam [197,198], continuous treatment with morphine [199], butanol [200] and N-methyl-d-aspartate (NMDA) [201]. Moreover, ACBP levels are also increased in liver, ovarian and brain tumors [202–205] and extraordinarily found in urine after chemotherapy of gall bladder cancer patients [206]. The expression level of the mammalian ACBP is also affected by feeding status.
Long-chain fatty acyl-CoA esters are key intermediates in numerous lipid metabolic pathways, and recognized as important cellular signaling molecules. The intracellular flux and regulatory properties of acyl-CoA esters have been proposed to be coordinated by acyl-CoA-binding domain containing proteins (ACBDs). The ACBDs, which comprise a highly conserved multigene family of intracellular lipid-binding proteins, are found in all eukaryotes and ubiquitously expressed in all metazoan tissues, with distinct expression patterns for individual ACBDs. The ACBDs are involved in numerous intracellular processes including fatty acid-, glycerolipid- and glycerophospholipid biosynthesis, β-oxidation, cellular differentiation and proliferation as well as in the regulation of numerous enzyme activities. Little is known about the specific roles of the ACBDs in the regulation of these processes, however, recent studies have gained further insights into their in vivo functions and provided further evidence for ACBD-specific functions in cellular signaling and lipid metabolic pathways. This review summarizes the structural and functional properties of the various ACBDs, with special emphasis on the function of ACBD1, commonly known as ACBP.
Secretome protein signature of human gastrointestinal stromal tumor cells
2015, Experimental Cell Research
Citation Excerpt :
By comparing the stimulated groups with the control group we revealed subsets of proteins being significantly released upon stimulation. In fact, the majority of the significantly elevated secretory proteins in the thapsigargin group (Table 2) have already been acknowledged in other tumor types, for example; trypsin and PEA-15 in colon cancers [54,55], RNA-binding protein FUS (fused in sarcoma) in myxoid liposarcoma [56], calpain small subunit 1, insulin-like growth factor-binding protein 7, and Acyl-CoA-binding protein in hepatocellular carcinomas [57–59], proteasome subunit alpha type-3 in esophageal cancer [60], inter-alpha-trypsin inhibitor heavy chain H4, fibulin-1, and protein CDV3 homolog in breast cancer [61–63], Apo A-I in ovarian cancer [64], Peroxiredoxin-5 in human lung carcinoma cells [65], glutathione S-transferase Mu 3 in gastric cancer [66], and neutral alpha-glucosidase AB in head and neck cancer [67]. It is also noteworthy that blocking the mutated c-KIT protein with imatinib radically changed the protein release pattern (Tables 2 and 4, Fig. 2).
Strategies for correct diagnosis, treatment evaluation and recurrence prediction are important for the prognosis and mortality rates among cancer patients. In spite of major improvements in clinical management, gastrointestinal stromal tumors (GISTs) can still be deadly due to metastasis and recurrences, which confirms the unmet need of reliable follow-up modalities. Tumor-specific secreted, shed or leaked proteins (collectively known as secretome) are considered promising sources for biomarkers, and suitable for detection in biofluids. Herein, we stimulated cell secretion in the imatinib-sensitive GIST882 cell line and profiled the secretome, collected as conditioned media, by using a shotgun proteomics approach. We identified 764 proteins from all conditions combined, 51.3% being predicted as classically/non-classically secreted. The protein subsets found were dependent on the stimulatory condition. The significant increase in protein release by the classical pathway was strongly associated with markers already found in other cancer types. Furthermore, most of the released proteins were non-classically released and overlapped to a high degree with proteins of exosomal origin. Imatinib pre-treatment radically changed these secretory patterns, which can have clinical implications when investigating biomarkers in imatinib-treated versus non-treated GIST patients. Our results show, for the first time, that GISTs contain a secretome signature. In the search for suitable biomarkers in the more complex GIST patient samples, this study aids in the understanding of basic GIST secretome characteristics.
Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion
2023, Advanced Science

View all citing articles on Scopus

View full text

Increased expression of peripheral benzodiazepine receptors and diazepam binding inhibitor in human tumors sited in the liver

Abstract

J. Biol. Chem.

Biochemical Pharmacology

Mo. Cell. Endocrinol.

Life Sci.

Biochem. Biophys. Acta

J. Biol. Chem.

J. Biol. Chem.

B. Regul. Pept.

Life Sci.

Blood

Life Sci.

Regul. Pept.

Gastroenterology

Pharmacology

Annu. Rev. Neurosci.

Mol. Pharmacol.